Kymera Therapeutics, Inc. Stock Price, News & Analysis

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), has scheduled its third quarter 2024 financial results announcement for October 31, 2024. The company will host a conference call at 8:30 a.m. ET on the same day. Investors can join via phone at +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International). A live webcast will be available on the company's website under the Investors section, with a replay available after the event.

Kymera Therapeutics announced three poster presentations at the EORTC-NCI-AACR Symposium, showcasing new preclinical data from its targeted protein degradation (TPD) platform. The presentations focus on KT-253, the company's MDM2 degrader currently in Phase 1 clinical trials for solid tumors and hematological malignancies. Using machine learning, researchers identified tumor types sensitive to KT-253, including acute myeloid leukemia, neuroendocrine tumors, and specific solid tumors. Additional presentations highlight the company's platform capabilities in developing CDK2 degraders and the effectiveness of MDM2 degraders in Merkel cell carcinoma.

Kymera Therapeutics (NASDAQ: KYMR) has announced FDA clearance of its Investigational New Drug (IND) application for KT-621, a first-in-class, oral STAT6 degrader. The company plans to initiate a Phase 1 clinical trial in healthy volunteers in October 2024, with data expected in the first half of 2025.

KT-621 has shown dupilumab-like activity and was well-tolerated in preclinical models of TH2 diseases. The Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of KT-621 compared to placebo.

Kymera believes that KT-621 has the potential to combine the complete pathway blockade of upstream biologics with the convenience of oral administration, potentially transforming the treatment paradigm for atopic and allergic diseases.

Kymera Therapeutics (NASDAQ: KYMR) presented preclinical data for KT-621, a potent, selective, oral STAT6 degrader, at the EADV Congress. KT-621 shows potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic diseases. The drug demonstrated strong degradation of STAT6 in human sensory neurons, inhibiting IL-13-induced itch- and pain-related gene transcripts, suggesting potential relief for atopic dermatitis symptoms.

Key highlights include:

• KT-621 expected to start Phase 1 in the second half of 2024, with data in the first half of 2025
• Preclinical studies show picomolar potency comparable or superior to dupilumab
• Demonstrated efficacy in atopic dermatitis and asthma mouse models
• Potential to expand patient access with a once daily, oral medicine for atopic dermatitis, asthma, and COPD

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation, has announced its participation in four major investor conferences this September. The events include:

• Wells Fargo 2024 Healthcare Conference in Boston (Sept 4)
• Morgan Stanley 22nd Annual Global Healthcare Conference in New York (Sept 5)
• H.C. Wainwright 26th Annual Global Investment Conference in New York (Sept 9)
• 2024 Cantor Fitzgerald Global Healthcare Conference in New York (Sept 17)

The company will engage in fireside chats and presentations at these events. Live webcasts will be available on Kymera's website, with replays archived for later viewing.

Kymera Therapeutics (NASDAQ: KYMR) has successfully closed its upsized public offering, raising $258.75 million in gross proceeds. The offering included 2,830,533 shares of common stock at $40.75 per share and pre-funded warrants for 3,519,159 shares at $40.7499 per warrant. The underwriters fully exercised their option to purchase additional shares. Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel acted as joint book-running managers for the offering. The securities were offered through an automatically effective shelf registration statement filed with the SEC on October 1, 2021.

Kymera Therapeutics (NASDAQ: KYMR) has priced a $225 million public offering of common stock and pre-funded warrants. The company is selling 2,002,313 shares at $40.75 per share and pre-funded warrants for 3,519,159 shares at $40.7499 each. Kymera has granted underwriters a 30-day option to purchase up to 828,220 additional shares. The offering is expected to close on August 21, 2024.

Proceeds will be used to advance Kymera's pipeline of preclinical and clinical degrader programs, for working capital, and other corporate purposes. The company may also use funds for in-licensing, acquisitions, or investments in complementary businesses or technologies. Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel are acting as joint book-running managers for the offering.

Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focusing on targeted protein degradation, has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option for an additional $30 million in shares. Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel are acting as joint book-running managers. Kymera intends to use the proceeds to advance its pipeline of preclinical and clinical degrader programs, for working capital, and potentially for in-licensing or acquiring complementary businesses or technologies. The offering is subject to market conditions and is being made through a shelf registration statement filed with the SEC.

Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Sanofi plans to expand KT-474/SAR444656 Phase 2 trials in HS and AD.

2. STAT6 degrader program on track for Phase 1 initiation in H2 2024.

3. TYK2 degrader program set to initiate and complete Phase 1 in 2025.

4. KT-253 (MDM2) and KT-333 (STAT3) oncology degrader programs showed major responses in clinical trials.

5. $702 million cash position as of June 30, 2024, with runway into H1 2027.

6. Q2 2024 collaboration revenues: $25.7 million; R&D expenses: $59.2 million; G&A expenses: $17.4 million; Net loss: $42.1 million.